Last checked at 28 Apr 2017 14:00
For immediate release 2.00pm: 28 April 2017
HVIVO PLC
("hVIVO" or the "Company")
2016 Annual Report and Financial Statements
hVIVO plc (AIM: HVO), a specialty biopharma company with clinical testing capabilities, is pleased to announce that its Annual Report and Financial Statements for the year ended 31 December 2016 is being posted to shareholders today. It will be available on the Company's website (http://hvivo.com/investors/financial-reports/) from 4.30 pm today.
For further information please contact:
hVIVO plc | +44 207 756 1300 |
Kym Denny (Chief Executive Officer) | |
Graham Yeatman (Chief Financial & Business Officer) | |
Media Enquiries | +44 203 021 3933 / +44 7854 979 420 |
Colin Paterson (Director of Marketing, Communication and Public Relations) | |
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) | |
James Black / Michael Burke (Corporate Broking) | |
FTI Consulting | |
Simon Conway / Victoria Foster Mitchell (UK) | +44 203 727 1000 |
John Capodanno / Evan Smith (US) | +1 212 850 5705 |
Notes to Editors:
hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.